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In a consortium including 23 637 breast cancer patients and 25 579 controls of East Asian ancestry, we inves-
tigated 70 single-nucleotide polymorphisms (SNPs) in 67 independent breast cancer susceptibility loci
recently identified by genome-wide association studies (GWASs) conducted primarily in European-ancestry
populations. SNPs in 31 loci showed an association with breast cancer risk at P < 0.05 in a direction consist-
ent with that reported previously. Twenty-one of them remained statistically significant after adjusting for
multiple comparisons with the Bonferroni-corrected significance level of <0.0015. Eight of the 70 SNPs
showed a significantly different association with breast cancer risk by estrogen receptor (ER) status at
P < 0.05. With the exception of rs2046210 at 6q25.1, the seven other SNPs showed a stronger association
with ER-positive than ER-negative cancer. This study replicated all five genetic risk variants initially identified
in Asians and provided evidence for associations of breast cancer risk in the East Asian population with
nearly half of the genetic risk variants initially reported in GWASs conducted in European descendants.
Taken together, these common genetic risk variants explain ∼10% of excess familial risk of breast cancer
in Asian populations.
INTRODUCTION
Breast cancer is one of the most common malignancies diag-
nosed among women worldwide, including East Asian women
(1). Genetic factors play an important role in the etiology of
both sporadic and familial breast cancer (2,3). Since 2007,
common genetic risk variants in approximately 25 loci have
been associated with breast cancer risk (3–18). However, with
only a few exceptions (9,13,14,16,18), the vast majority of
these risk variants were initially identified in studies conducted
in European descendants (4–8,10–12,15,17). Several previous
studies have evaluated some of these risk variants in relation to
breast cancer risk in non-European populations (19–26), includ-
ing East Asian women (19,24–26). Sample sizes in these
studies, however, were small, and only a few variants were
evaluated. Recently, as part of the international Collaborative
Oncological Gene-Environment Study (COGS), 42 additional
genetic susceptibility loci for breast cancer risk were identified
in genome-wide association studies (GWASs) conducted in
European descendants (27).
Given differences in genetic architecture, breast cancer inci-
dence rates and environmental exposures across different
ethnic populations, it is important to systematically investigate
whether these genetic risk variants are associated with breast
cancer risk in other ethnic populations. This investigation
not only assesses the generalizability of initial GWAS findings
but also provides valuable data to guide fine-mapping efforts
in the search for disease variants. In this study, we combined
data generated in the Asia Breast Cancer Consortium (ABCC)
with Asian samples from COGS to systematically evaluate
risk variants in all 67 loci identified to date.
RESULTS
This study combined data obtained from 41 586 women (19
963 cases and 21 623 controls) included in the ABCC and
2540 Human Molecular Genetics, 2013, Vol. 22, No. 12
12 893 women (6269 cases and 6624 controls) included in
COGS. All study participants were of Asian ancestry and
recruited from studies conducted in Asian countries and the
USA (Table 1 and Supplementary Material, Table S1). The
ABCC consisted of two stages. Stage 1 included two
GWASs, in which 5285 Chinese women and 4777 Korean
women were scanned using primarily Affymetrix Genome-
Wide Human SNP Array 6.0 [906 602 single-nucleotide poly-
morphisms (SNPs)]. After applying quality-control (QC)
filters described previously (9,18,24), 5242 Chinese women
(2918 cases and 2324 controls; 690 947 SNPs) and 4298
Korean women (2246 cases and 2052 controls; 555 525
SNPs) remained in the GWASs. These data were used to
impute autosomal SNPs present in HapMap II release 22
using the MACH program v1.0 (28). Only SNPs with high im-
putation quality [R-squared (RSQ) . 0.50] were included in
the analysis. To increase statistical power, we genotyped add-
itional samples included in Stage 2 of the ABCC for 44 of the
70 SNPs identified in GWASs (called index SNPs in subse-
quent text). As part of a large collaboration of GWASs of mul-
tiple cancer sites (27), COGS samples were genotyped on a
custom Illumina Infinium BeadChip, which included either
index SNPs (n ¼ 67) or SNPs (n ¼ 2) in strong linkage dis-
equilibrium (LD) (r2. 0.8), with the index SNPs selected
for the data analysis of this study.
Evaluation of SNPs in 26 previously reported loci in
Europeans and Asians
One index SNP per locus was selected for most of the previ-
ously reported loci, except for 10q21/ZNF365 and 16q12/
TOX3, for which two SNPs were selected per locus as they
are not in LD in Asians. For 17 of the 28 SNPs, de novo geno-
typing was conducted for additional samples (ranging from
3348 to 27 166) included in the ABCC as part of previous
studies (Stage 2) (9,13,14,18,19,23,26,29). A meta-analysis
of ABCC Stages 1 and 2 data was performed under the
fixed-effects model (30), and results are presented in Table 2
(left panel). Detailed stage-specific results are presented in
Supplementary Material, Table S2. Table 2 also includes
results obtained from Asian women included in COGS
(middle panel), as well as combined results generated by a
meta-analysis of data from the ABCC and COGS (right
panel). Heterogeneity tests for associations of these SNPs
Table 1. Summary of characteristics of study participants















SBCGS1e 2918 2324 Chinese Population-based 52/50 43/42 65 62
SBCGS2e 1613 1800 Chinese Population-based 53/53 50/55 62 58
SBCGS3e 2601 2386 Chinese Population-based 54/55 50/53 65 58
Taiwan 1066 1065 Chinese Hospital-based 52/48 52/40 66 65
Hong Kong 491 642 Chinese Hospital-based 46/46 50/42 71 60
Guangzhou 1083 1224 Chinese Hospital-based 49/50 43/54 70 61
Tianjin 1546 1601 Chinese Hospital-based 52/52 52/55 44 44
Nanjing 1786 1837 Chinese Hospital-based 51/50 51/48 56 56
SeBCS1 2246 2052 Korean Hospital-based 48/51 36/56 63 56
SeBCS2 777 1104 Korean Hospital-based 48/48 36/37 63 53
KOHBRA/
KoGES
1397 3209 Korean Hospital-based 40/50 23/NA 63 63
Korea-NCC 505 504 Korean Hospital-based 49/49 50/45 65 58
Nagoya 644 644 Japanese Hospital-based 51/51 49/49 73 100
Nagano 401 401 Japanese Hospital-based 54/54 55/65 75 60
MEC 889 830 Japanese Cohort 67/66 NA/NA 85 76
Subtotal 19 963 21 623
COGS
SBCGS 848 892 Chinese Population-based 55/53 42/43 65 65
SeBCS 1162 1129 Korean Hospital-based 49/52 41/NA 64 60
TWBCS 889 236 Chinese Hospital-based 52/51 52/52 70 69
HERPACC 694 1376 Japanese Hospital-based 52/51 49/49 74 63
ACP 423 636 Chinese/Thai Hospital-based 46/47 42/41 63 NA
MyBrCa 770 610 Asiansf Hospital-based 49/49 53/61 60 52
SGBCC 533 502 Asiansf Hospital-based 52/50 NA 72 74
TBCS 138 253 Thai Hospital-based 46/42 53/32 50 NA
LAABC 812 990 Chinese/Japanese Population-based 54/51 60/46 74 69
Subtotal 6269 6624
Totalg 23 637 25 579
ABCC, Asia Breast Cancer Consortium; COGS, International Collaborative Oncological Gene-Environment Study; NA, not available.
aUnless otherwise specified, case–control study design was used.
bMean age of cases/controls with available data.
cProportion of postmenopausal status of cases/controls with available data.
dAmong cases with ER or PR data.
eCases and controls from four studies conducted in Shanghai (see Materials and Methods).
fIncluding Chinese, Malays and Indians.
gExcluding overlapping samples included in both ABCC and COGS.
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Table 2. Associations of breast cancer risk with SNPs located in 26 previously reported breast-cancer susceptibility loci: results from East Asian women
SNPa Chr./geneb Positionc (bp) Allelesd EAFe ABCC samples COGS samples Combinedh
OR (95% CI)f,g Ptrend OR (95% CI)
f Ptrend Cases/controls OR (95% CI)
f Pmeta Pheterogeneity
i
Loci initially identified in Asians
rs9485372 6q25/TAB2 149 650 567 A/G 0.453 0.90 (0.87–0.92) 4.66 × 10212 0.89 (0.84–0.94) 7.64 × 1026 19 893/21 663 0.90 (0.87–0.92) 2.27 × 10213 0.599
rs2046210 6q25/ESR1 151 990 059 A/G 0.342 1.27 (1.23–1.31) 2.59 × 10250 1.28 (1.22–1.35) 2.81 × 10220 22 313/23 063 1.27 (1.24–1.31) 1.95 × 10262 0.702
rs10822013 10q21/ZNF365 63 921 983 T/C 0.469 1.09 (1.06–1.13) 7.98 × 1029 1.05 (1.00–1.10) 0.075 21 578/22 364 1.08 (1.05–1.11) 2.98 × 1028 0.133
rs7107217 11q24/BARX2 128 978 900 C/A 0.352 1.08 (1.05–1.12) 2.11 × 1027 1.09 (1.03–1.15) 0.002 21 545/23 560 1.08 (1.05–1.11) 6.69 × 1028 0.752
rs4784227 16q12/TOX3 51 156 689 T/C 0.247 1.27 (1.22–1.32) 4.58 × 10231 1.20 (1.12–1.27) 1.86 × 1028 18 459/16 622 1.24 (1.20–1.29) 2.83 × 10232 0.155
Loci initially identified in Europeans
rs11249433 1p11/FCGR1B 120 982 136 G/A 0.030 1.13 (0.98–1.30) 0.101 1.18 (1.03–1.35) 0.018 11 937/11 667 1.16 (1.05–1.28) 0.005 0.743
rs13387042 2q35/TNP1 217 614 077 G/A 0.895 0.93 (0.86–1.01) 0.080 0.95 (0.88–1.03) 0.226 12 063/11 874 0.94 (0.88–0.99) 0.022 0.493
rs4973768 3p24/SLC4A7 27 391 017 T/C 0.192 1.12 (1.06–1.19) 8.73 × 1025 1.11 (1.05–1.18) 7.18 × 1024 13 504/12 111 1.11 (1.06–1.16) 4.93 × 1026 0.920
rs10069690 5p15/TERT 1 332 790 T/C 0.224 1.01 (0.92–1.11) 0.808 1.04 (0.98–1.11) 0.188 10 328/9870 1.05 (0.99–1.11) 0.103 0.865
rs10941679 5p12/MRPS30 44 742 255 G/A 0.484 1.09 (1.04–1.14) 6.74 × 1024 1.09 (1.04–1.15) 8.20 × 1024 12 066/11 875 1.08 (1.04–1.12) 2.24 × 1025 0.706
rs889312 5q11/MAP3K1 56 067 641 A/C 0.477 0.95 (0.90–1.00) 0.037 0.94 (0.89–0.99) 0.013 12 070/11 879 0.95 (0.92–0.99) 0.013 0.325
rs2180341 6q22/RNF146 127 642 323 A/G 0.740 1.01 (0.96–1.07) 0.607 NA NA 7049/6364 1.01 (0.96–1.07) 0.607 NA
rs13281615 8q24/MYC 128 424 800 G/A 0.522 1.03 (0.98–1.08) 0.199 1.02 (0.97–1.08) 0.388 12 077/11 876 1.03 (0.99–1.07) 0.103 0.665
rs1011970 9p21/CDKN2A/2B 22 052 134 T/G 0.081 1.03 (0.93–1.14) 0.599 1.06 (0.97–1.16) 0.178 10 328/9870 1.06 (0.99–1.14) 0.112 0.893
rs865686 9q31/KLF4 109 928 299 T/G 0.934 0.99 (0.89–1.12) 0.927 1.06 (0.96–1.17) 0.213 10 328/9870 1.04 (0.96–1.12) 0.389 0.354
rs2380205 10p15/ANKRD16 5 926 740 T/C 0.106 0.92 (0.84–1.01) 0.093 1.00 (0.92–1.07) 0.927 10 328/9870 0.98 (0.92–1.04) 0.501 0.426
rs10995190 10q21/ZNF365 63 948 688 A/G 0.022 0.89 (0.73–1.10) 0.284 1.17 (1.00–1.38) 0.057 10 328/9870 1.06 (0.93–1.22) 0.361 0.041
rs704010 10q22/ZMIZ1 80 511 154 C/T 0.706 0.94 (0.88–1.00) 0.056 0.95 (0.90–1.00) 0.070 10 328/9870 0.95 (0.91–0.99) 0.013 0.772
rs1219648 10q26/FGFR2 123 336 180 G/A 0.367 1.16 (1.11–1.21) 1.63 × 10212 1.12 (1.07–1.18) 1.21 × 1025 15 130/14 584 1.14 (1.10–1.18) 2.90 × 10213 0.476
rs3817198 11p15/LSP1 1 865 582 C/T 0.128 1.03 (0.96–1.11) 0.346 1.07 (0.99–1.15) 0.080 13 655/12 083 1.07 (1.01–1.13) 0.015 0.938
rs614367 11q13/CCND1 69 037 945 T/C NA NA NA 1.29 (1.06–1.58) 0.013 6269/6624 1.29 (1.06–1.58) 0.013 NA
rs10771399 12p11/PTHLH 28 046 347 G/A 0.191 0.88 (0.81–0.94) 5.30 × 1024 0.87 (0.81–0.93) 4.91 × 1025 10 328/9870 0.87 (0.83–0.92) 2.47 × 1027 0.920
rs1292011 12q24/MED13L 114 320 905 G/A 0.257 0.92 (0.86–0.99) 0.029 0.89 (0.84–0.95) 1.48 × 1024 10 328/9870 0.90 (0.86–0.94) 1.38 × 1025 0.668
rs999737 14q24/RAD51L1 68 104 435 T/C 0.001 1.96 (0.94–4.07) 0.072 0.95 (0.68–1.33) 0.764 10 772/10 711 1.08 (0.80–1.46) 0.628 0.075
rs3803662 16q12/TOX3 51 143 842 G/A 0.360 0.86 (0.82–0.91) 4.84 × 1029 0.85 (0.81–0.90) 3.97 × 1029 13 606/12 064 0.87 (0.84–0.90) 7.83 × 10214 0.444
rs6504950 17q22/STXBP4 50 411 470 A/G 0.072 1.01 (0.93–1.11) 0.757 0.98 (0.90–1.07) 0.685 13 642/12 111 0.98 (0.92–1.05) 0.642 0.926
rs8170 19p13/BABAM1 17 250 704 A/G NA NA NA 1.10 (0.76–1.61) 0.605 6269/6624 1.10 (0.76–1.61) 0.605 NA
rs2823093 21q21/NRIP1 15 442 703 A/G 0.034 0.94 (0.80–1.11) 0.495 0.91 (0.80–1.03) 0.147 10 328/9870 0.93 (0.84–1.04) 0.200 0.486
Chr., chromosome; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval; ABCC, Asia Breast Cancer Consortium; NA, not available; COGS, International Collaborative Oncological
Gene-Environment Study.
aSNPs in high LD with the index SNPs were used in COGS samples: rs9485370 for rs9485372 (r2 ¼ 1.0) and rs17271951 for rs4784227 (r2 ¼ 0.81) based on Asian data from HapMap release27.
bThe closest gene.
cLocation based on NCBI Human Genome Build 36.3.
dEffect/reference alleles based on NCBI Human Genome Build 36.3, dbsnp b126 forward strand.
eEffect allele frequency in controls from the ABCC samples. EAFs from the COGS samples are similar to those presented in the table.
fAdjusted for age and study site if appropriate.
gData described in studies reported in references (9,13,14,18,19,23,26,29) were included in this analysis.
hCombined results for all available studies after excluding samples that overlapped in both ABCC and COGS.



































between the ABCC and COGS were statistically significant
only for rs10995190/ZNF365 (P ¼ 0.04), for which the
minor allele frequency (MAF) is only 0.02 in Asians. Of the
28 SNPs evaluated, 17 showed associations with breast
cancer risk at P , 0.05 in Asian women in the same direction
as previously reported, and 11 of them remained statistically
significant after adjusting for multiple comparisons of 67
SNPs with the Bonferroni-corrected significance level of
0.0015 (0.10/67, one-sided test). However, the effect size—
measured using per-allele odds ratios (ORs) in Asians—was
smaller than that initially identified in Europeans (Fig. 1),
and the difference was statistically (P, 0.05) or marginally
(P , 0.06) significant for six of the replicated SNPs (Supple-
mentary Material, Table S3). Five breast cancer-associated
signals were previously discovered in Asian GWASs
(9,13,14,18), and all of them were replicated in COGS
samples with a combined P-value of 1.95 × 10262 for
rs2046210 (6q25.1/ESR1), 2.83 × 10232 for rs4784227
(16q12/TOX3), 2.27 × 10213 for rs9485372 (6q25/TAB2),
2.98 × 1028 for rs10822013 (10q21/ZNF365) and 6.69 ×
1028 for rs7107217 (11q24/BARX2). In the 10q21/ZNF365
locus, rs10995190, identified initially in a GWAS of European
descendants, was not related to breast cancer risk in Asians,
whereas the association with rs10822013, identified initially
in the ABCC (14), was replicated in COGS samples with a
borderline significant P-value. At 16q12.1/TOX3, associations
with both rs4784227 and rs3803662 remained statistically sig-
nificant after mutual adjustment (Table 3). Of the 11 SNPs not
replicated in our study, 4 have a very low MAF (≤0.05) in
Asians, whereas the rest show very weak associations, with
allelic ORs ranging from 0.93 to 1.06. The CASP8 SNP
(rs1045485) identified previously through a candidate gene
study (4) has a very low MAF in Asians and was not replicated
in the study (data not shown in the table). Additional analyses
were performed to evaluate the association of the 17 replicated
SNPs by major study populations included in this study,
Chinese, Koreans and Japanese (Supplementary Material,
Table S4). With the exception of rs889312 (P ¼ 0.002) and
rs3817198 (P ¼ 0.012), the remaining 15 SNPs showed a con-
sistent association in Chinese, Koreans and Japanese. SNPs
rs889312 and rs3817198 were statistically associated with
breast cancer risk only in Koreans and Chinese, respectively.
Because of a small sample size, only three SNPs
(rs2046210, rs1219648 and rs4784227) were found to be asso-
ciated with breast cancer in Japanese at P , 0.05.
Evaluation of SNPs in 42 newly identified loci in Europeans
In addition to GWAS data, we genotyped 27 index SNPs in
7294 cases and 9404 controls included in the ABCC. Results
for this analysis are presented in Table 4 and Supplementary
Material, Table S5. Of the 42 SNPs evaluated (1 SNP per
locus), 16 showed associations with breast cancer risk at
P , 0.05 in the same direction reported in European-ancestry
populations (27). Of them, 10 remained statistically significant
after adjusting for multiple comparisons (P, 0.0015).
Adjusted allelic ORs for the replicated SNPs ranged from
0.92 to 1.16, showing a smaller effect size than those pre-
sented in Table 2. SNP rs11820646 at 11q24 is correlated
with rs7217217 (r2 ¼ 0.386 in Asian and r2 ¼ 0.842 in
CEU) identified initially in the ABCC (18) and replicated in
Asian samples included in COGS (Table 2). The association
with rs7107217 remained after adjusting for rs11820646
(P ¼ 2.73 × 1024) (Table 3). On the other hand, adjusting
for rs7107217 diminished the association with rs11820646,
suggesting that rs7107217 may tag the disease variant better
than rs11820646 in East Asians. Of the 22 non-replicated
SNPs, 3 have a small MAF in both Asia and European
samples (based on the HapMap data), including rs132390
(500 kb downstream to the CHEK2 gene), rs11571833
(BRCA2) and rs11814448 (10p12). The MAF for the other
Figure 1. Correlation of effect allele frequency (A) and effect size measured in per-allele ORs (B) between East Asians and European-ancestry populations for 60
index SNPs identified initially in GWASs conducted in European descendants (filled triangle for SNPs replicated in Asians, filled circle for SNPs not replicated
in Asians).
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six SNPs (rs1353747, rs720475, rs7072776, rs7904519,
rs2588809 and rs13329835) also was very low (,0.05) in
Asian samples but not in European samples (mean MAF ¼
0.23) included in the HapMap project. With the exception of
three SNPs (rs11242675, rs17817449 and rs3760982), hetero-
geneity tests were not statistically significant for SNPs
between ABCC and COGS samples. Again, the effect size
for most of the SNPs in Asians was smaller than those identi-
fied in Europeans (Fig. 1), and the difference was statistically
significant for four SNPs (Supplementary Material, Table S3).
We also performed subgroup analysis for the 16 replicated
SNPs by Chinese, Korean and Japanese (Supplementary Ma-
terial, Table S4). Only four SNPs (rs11242675, rs11780156,
rs11199914 and rs4808801) showed some evidence of hetero-
geneity (P , 0.05) in their associations with breast cancer risk
in the three populations. In Japanese, however, only two SNPs
showed a statistically significant association (rs7697216 and
rs4808801), likely due to a small sample size in this group.
Associations by ER status
Of the 70 SNPs in 67 loci evaluated, SNPs in 8 loci showed a
significantly different association with breast cancer risk by
ER status at P, 0.05 (Table 5 and Supplementary Material,
Table S6). With the exception of rs2046210/6q25, the seven
other SNPs showed a stronger association with ER-positive
cancer compared with ER-negative cancer. In fact, six of the
eight SNPs showed no significant association with ER-negative
cancer except rs2046210/6q25 (per allele OR ¼ 1.36, P ¼
6.04 × 10249) and rs1219648/FGFR2 (per allele OR ¼ 1.08,
P ¼ 0.0055). Details of all evaluated SNPs by ER status are pre-
sented in Supplementary Material, Table S6.
DISCUSSION
By analyzing data from up to 23 637 breast cancer cases and
25 579 controls of Asian ancestry, we identified a significant
association at P , 0.05 for 31 of the 67 independent breast
cancer association signals reported from previous GWASs
conducted mostly in European descendants. The number of
SNPs identified in our study with a significant association at
P, 0.05 was substantially greater than the 1.68 significant
associations expected by chance under a null hypothesis
(67 × 0.025 ¼ 1.675). Twenty-one of these associations
remained statistically significant after adjusting for multiple
comparisons using the Bonferroni-corrected P-value of
0.0015. Our study has substantially boosted the number of
genetic risk variants identified to date for East Asian
women. Together, these SNPs explain 10% of the excess fa-
milial risk for breast cancer among East Asian women
(Supplementary Material, Table S7).
This study represents the largest, most comprehensive effort
made to date to evaluate the generalizability of GWAS find-
ings to any non-European population. With 23 637 cases and
25 579 controls included in the study, the statistical power
was very large. For some analyses, however, only about
10 200 cases and 9800 controls were included. Even in this
sample size set, we still have 85% power to detect associations
with ORs as low as 1.10 for an MAF of 0.10 or above (Sup-
plementary Material, Table S8). This study was designed to
directly evaluate risk variants identified in previous GWASs,
and thus, SNPs showing an association at P , 0.05 in the
same direction as previously reported were considered statis-
tically significant. It is possible, however, that some of the sig-
nificant findings (n ¼ 1.68) could be due to chance because of
multiple comparisons. Nevertheless, we also presented find-
ings based on a more stringent significant level with the ad-
justment for multiple comparisons.
Differences in LD patterns between East Asian- and
European-ancestry populations are likely to be the major reason
for the lack of replication for some of the index SNPs in our
study. The vast majority of non-replicated SNPs showed a sub-
stantial difference in the frequency of the effect alleles (Fig. 1
and Supplementary Material, Table S9). Fourteen SNPs which
did not replicate had very small MAFs in East Asian women
(mean ¼ 0.0176) but much higher MAFs in European descen-
dants (mean¼ 0.177) (P, 0.001) (Supplementary Material,
Table S9). Most SNPs with an association identified by
GWASs are tagging SNPs of the disease variant(s). Because of
the differences in LD patterns between East Asian and European
Table 3. Conditional analysis for the association of breast cancer risk with SNPs in four loci for which more than one risk variant was reported: results from East
Asian women
Locus Cases/controls SNPsa EAFb LD (r2)c Per-allele association
(Asian/CEU) OR (95% CI)d Ptrend
10q21/ZNF365 5164/4376 rs10822013e 0.467 0.026/0.157 1.09 (1.04–1.15) 2.92 × 1024
rs10995190 0.022 0.88 (0.72–1.08) 0.237
10q26/FGFR2 9173/6588 rs1219648 0.364 0.639/1.000 1.12 (1.02–1.23) 0.022
rs2981582 0.706 0.97 (0.88–1.07) 0.527
11q24/BARX2 12 254/13 586 rs7107217e 0.357 0.386/0.842 1.10 (1.04–1.15) 2.73 × 1024
rs11820646 0.555 1.00 (0.95–1.05) 0.909
16q12/TOX3 9024/6139 rs3803662 0.362 0.139/0.813 0.92 (0.88–0.98) 0.005
rs4784227e 0.251 1.21 (1.14–1.28) 3.87 × 10210
aSNPs included in the same logistic regression model.
bEffect allele frequency in controls.
cBased on Asian data from HapMap release 22.
dAdjusted for age and study site if appropriate.
eSNPs identified initially in GWASs conducted in East Asians (13,14,18).
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Table 4. Associations of breast cancer risk with SNPs located in 42 recently reported breast-cancer susceptibility loci: results from East Asian women
SNPa Chr./geneb Positionc (bp) Allelesd EAFe ABCC samples COGS samples Combinedg
OR (95% CI)f Ptrend OR (95% CI)
f Ptrend Cases/controls OR (95% CI)
f Pmeta Pheterogeneity
h
rs616488 1p36/PEX14 10 488 802 G/A 0.314 0.93 (0.89–0.96) 1.01 × 1024 0.95 (0.90–1.01) 0.096 17 477/19 133 0.94 (0.91–0.97) 3.41 × 1024 0.517
rs11552449 1p13/AP4B1 114 249 912 T/C 0.608 1.03 (0.99–1.07) 0.179 1.02 (0.97–1.07) 0.523 17 447/19 114 1.03 (0.99–1.06) 0.131 0.679
rs4849887 2q14/INHBB 120 961 592 C/T 0.817 1.08 (1.03–1.13) 8.35 × 1024 1.04 (0.97–1.11) 0.245 17 471/19 143 1.07 (1.03–1.11) 0.001 0.282
rs2016394 2q31/DLX2 172 681 217 A/G 0.186 0.98 (0.90–1.08) 0.733 1.00 (0.94–1.07) 0.974 10 328/9870 0.99 (0.94–1.05) 0.790 0.616
rs1550623 2q31/CDCA7 173 921 140 A/G 0.992 1.47 (0.89–2.42) 0.131 1.15 (0.93–1.40) 0.190 10 328/9870 1.21 (1.00–1.47) 0.054 0.097
rs16857609 2q35/DIRC3 218 004 753 T/C 0.589 1.07 (1.03–1.10) 5.09 × 1024 1.06 (1.01–1.12) 0.018 17 452/19 120 1.07 (1.04– –1.10) 2.31 × 1025 0.816
rs6762644 3p26/ITPR1 4 717 276 G/A 0.079 1.02 (0.96–1.09) 0.483 1.07 (0.98–1.17) 0.151 17 481/19 143 1.03 (0.98–1.09) 0.286 0.324
rs12493607 3p24/TGFBR2 30 657 943 C/G 0.673 1.07 (1.01–1.14) 0.024 1.04 (0.99–1.10) 0.133 10 328/9870 1.05 (1.01–1.10) 0.019 0.547
rs9790517 4q24/TET2 106 304 227 T/C 0.611 1.04 (0.98–1.10) 0.191 1.00 (0.95–1.06) 0.882 10 328/9870 1.02 (0.98–1.06) 0.342 0.321
rs7697216 4q34/ADAM29 176 064 611 C/T 0.758 1.07 (1.03–1.12) 9.99 × 1024 1.08 (1.02–1.14) 0.014 17 437/19 127 1.07 (1.04–1.11) 1.16 × 1024 0.889
rs10472076 5q11/RAB3C 58 219 818 C/T 0.270 1.02 (0.98–1.07) 0.242 0.99 (0.94–1.05) 0.745 17 476/19 184 1.02 (0.98–1.05) 0.375 0.279
rs1353747 5q11/PDE4D 58 373 238 G/T NA NA NA 0.82 (0.57–1.20) 0.316 6269/6624 0.82 (0.57–1.20) 0.316 NA
rs1432679 5q33/EBF1 158 176 661 T/C 0.336 0.92 (0.88–0.96) 2.07 × 1025 0.92 (0.87–0.97) 0.001 17 107/19 040 0.92 (0.89–0.96) 2.79 × 1026 0.730
rs11242675 6p25/FOXQ1 1 263 878 T/C 0.480 1.01 (0.97–1.04) 0.751 0.93 (0.89–0.98) 0.008 17 425/19 030 0.99 (0.96–1.03) 0.703 0.003
rs204247 6p23/RANBP9 13 830 502 A/G 0.384 0.97 (0.94–1.01) 0.164 0.96 (0.91–1.01) 0.081 17 444/19 128 0.97 (0.94–1.00) 0.085 0.383
rs17529111 6q14/FAM46A 82 185 105 C/T 0.198 1.07 (0.99–1.15) 0.080 1.03 (0.97–1.10) 0.326 10 328/9870 1.04 (0.99–1.09) 0.152 0.793
rs720475 7q35/ARHGEF5 143 705 862 A/G 0.026 1.00 (0.89–1.12) 0.982 0.96 (0.84–1.10) 0.579 17 494/19 157 0.98 (0.89–1.07) 0.619 0.765
rs9693444 8p21/RPL17P33 29 565 535 C/A 0.706 0.92 (0.88–0.95) 1.83 × 1025 0.93 (0.88–0.98) 0.008 17 448/19 112 0.93 (0.90–0.96) 1.01 × 1025 0.970
rs6472903 8q21/HNF4G 76 392 856 T/G 0.957 1.16 (1.05–1.28) 0.003 1.15 (1.01–1.30) 0.040 17 480/19 190 1.16 (1.07–1.26) 4.23 × 1024 0.839
rs2943559 8q21/HNF4G 76 580 492 G/A 0.107 1.03 (0.93–1.13) 0.600 0.94 (0.86–1.02) 0.154 10 328/9870 0.96 (0.90–1.03) 0.299 0.325
rs11780156 8q24/MYC 129 263 823 T/C 0.216 1.01 (0.97–1.05) 0.707 0.99 (0.93–1.06) 0.834 17 472/19 143 1.00 (0.96–1.04) 0.973 0.775
rs10759243 9q31/KLF4 109 345 936 C/A 0.579 0.95 (0.90–1.01) 0.102 0.94 (0.89–0.99) 0.017 10 328/9870 0.95 (0.91–0.99) 0.008 0.653
rs7072776 10p12/MLLT10 22 072 948 G/A 0.972 0.88 (0.73–1.04) 0.136 1.01 (0.90–1.13) 0.876 10 328/9870 0.96 (0.87–1.06) 0.424 0.095
rs11814448 10p12/DNAJC1 22 355 849 C/A 0.005 1.08 (0.84–1.39) 0.548 1.08 (0.85–1.38) 0.527 17 291/19 079 1.08 (0.90–1.30) 0.389 1.000
rs7904519 10q25/TCF7L2 114 763 917 G/A 0.042 1.01 (0.88–1.17) 0.866 1.06 (0.94–1.19) 0.347 10 328/9870 1.02 (0.93–1.12) 0.638 0.342
rs11199914 10q26/FGFR2 123 083 891 T/C 0.396 0.96 (0.91–1.02) 0.193 0.98 (0.93–1.03) 0.441 10 328/9870 0.97 (0.93–1.01) 0.148 0.551
rs12575663 11q13/OVOL1 65 331 111 A/G 0.175 1.00 (0.95–1.04) 0.880 0.94 (0.88–1.00) 0.040 17 462/19 133 0.98 (0.94–1.01) 0.211 0.104
rs11820646 11q24/BARX2 128 966 381 C/T 0.555 1.06 (1.02–1.10) 0.002 1.04 (0.99–1.10) 0.129 17 479/19 136 1.05 (1.01–1.08) 0.004 0.790
rs12422552 12p13/ATF7IP 14 305 198 C/G 0.275 1.06 (0.99–1.14) 0.099 1.06 (1.00–1.12) 0.035 10 328/9870 1.05 (1.00–1.10) 0.043 0.431
rs17356907 12q22/NTN4 94 551 890 G/A 0.227 0.94 (0.90–0.98) 0.004 0.92 (0.87–0.97) 0.005 17 460/19 120 0.93 (0.90–0.97) 1.99 × 1024 0.513
rs11571833 13q13/BRCA2 31 870 626 T/A NA NA NA 2.21 (0.70–6.97) 0.177 6269/6624 2.21 (0.70–6.97) 0.177 NA
rs2236007 14q13/PAX9 36 202 520 A/G 0.246 0.91 (0.87–0.95) 1.93 × 1025 0.93 (0.88–0.99) 0.014 17 499/19 186 0.92 (0.89–0.95) 5.61 × 1026 0.609
rs2588809 14q24/RAD51L1 67 730 181 C/T 0.978 0.92 (0.81–1.03) 0.157 0.97 (0.84–1.11) 0.646 17 490/19 146 0.94 (0.86–1.04) 0.225 0.618
rs941764 14q32/CCDC88C 90 910 822 G/A 0.138 1.06 (1.01–1.11) 0.029 1.02 (0.95–1.10) 0.507 17 467/19 134 1.05 (1.01–1.10) 0.025 0.385
rs17817449 16q12/FTO 52 370 868 G/T 0.124 0.88 (0.83–0.93) 6.79 × 1026 1.01 (0.94–1.08) 0.868 16 797/18 983 0.92 (0.88–0.97) 5.78 × 1024 0.001
rs13329835 16q23/DYL2 79 208 306 G/A 0.051 1.05 (0.97–1.13) 0.260 1.04 (0.93–1.17) 0.488 17 482/19 192 1.02 (0.96–1.10) 0.483 0.735
rs527616 18q11/AQP4 22 591 422 G/C 0.692 1.04 (1.00–1.08) 0.067 1.01 (0.95–1.07) 0.818 17 466/19 127 1.03 (1.00–1.07) 0.065 0.269
rs1436904 18q11/CHST9 22 824 665 G/T 0.453 0.99 (0.93–1.05) 0.692 1.00 (0.95–1.05) 0.931 10 328/9870 0.98 (0.95–1.02) 0.440 0.391
rs4808801 19p13/ELL 18 432 141 G/A 0.252 0.95 (0.91–0.99) 0.016 0.97 (0.91–1.03) 0.300 17 316/19 098 0.96 (0.92–0.99) 0.018 0.624
rs3760982 19q13/KCNN4 48 978 353 G/A 0.865 0.96 (0.91–1.01) 0.091 1.05 (0.98–1.12) 0.148 17 570/19 207 0.98 (0.94–1.03) 0.464 0.012
rs132390 22q12/EMID1 27 951 477 T/C NA NA NA 0.93 (0.54–1.59) 0.787 6269/6624 0.93 (0.54–1.59) 0.787 NA
rs6001930 22q13/MKL1 39 206 180 C/T 0.278 1.03 (0.99–1.07) 0.192 1.05 (0.99–1.12) 0.092 17 450/19 129 1.03 (1.00–1.07) 0.063 0.463
Chr., chromosome; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval; ABCC, Asia Breast Cancer Consortium; NA, not available; COGS, International Collaborative Oncological
Gene-Environment Study.
aSNPs in complete LD (r2 ¼ 1.0, based on Asian data from HapMap release27) with index SNPs were used in this study: rs7697216 for rs6828523, and rs12575663 for rs3903072.
bThe closest gene.
cLocation based on NCBI Human Genome Build 36.3.
dEffect/reference alleles based on NCBI Human Genome Build 36.3, dbsnp b126 forward strand.
eEffect allele frequency in controls from the ABCC samples. EAFs from the COGS samples are similar to those presented in the table.
fAdjusted for age and study site if appropriate.
gCombined results for all available studies after excluding samples that overlapped in both ABCC and COGS.


































populations, some of the SNPs identified by GWASs may be
more closely associated with disease variants in European-ances-
try populations compared with East Asian populations, which
may partially explain the weaker association for some index
SNPs in East Asians than European-ancestry populations. Thus,
fine-mapping of these regions in both Asian and European popu-
lations may be fruitful in identifying relevant disease variants.
Our findings for SNPs located at 10q21/ZNF365 illustrate
how differences in LD patterns may result in a different
SNP being identified by a GWAS. One SNP at 10q21/
ZNF365 (rs10822013, OR ¼ 1.10, P ¼ 5.87 × 1029) was
reported previously to be associated with breast cancer risk
in a GWAS conducted in East Asians (14). This SNP is
26.7 kb upstream of rs10995190, which was identified inde-
pendently in a GWAS conducted in European descendants
(12). Interestingly, rs10995190, a common SNP in European
descendants (MAF ¼ 0.13), is rare in East Asians (MAF ¼
0.02). It is likely that the disease variants are tagged by differ-
ent SNPs in East Asians (rs10822013) and Europeans
(rs10995190) in this region. SNPs at 16q12.1/TOX3 also are
of interest. The two top breast cancer-associated SNPs in
this region identified to date are rs4784227 and rs3803662.
These two SNPs, however, are highly correlated in Europeans
(r2 ¼ 0.813) but virtually not correlated in Asians (r2 ¼
0.139). Although rs4784227 showed a stronger association
with breast cancer risk than rs3803662 in Asians, the associ-
ation with rs3803662 remained statistically significant after
adjustment for rs4784227, suggesting the existence of a
second disease variant in this region (18). In vitro experiments
have provided evidence for functional significance of
rs4784227 (30). The differences in LD patterns across ethnic
groups may help to narrow the region of interest and/or the
number of candidate SNPs for fine-mapping analyses to iden-
tify disease variants.
The lack of association with index SNPs in some loci could
also be explained by allelic heterogeneity, in which different
underlying disease variants exist in Asian- and European-an-
cestry populations, or by possible differences between these
populations in genetic and environmental modifiers. In addition
to differences in LD patterns between East Asian and European
populations, and possible allelic heterogeneity in these popula-
tions, other factors may have contributed to weaker associa-
tions observed in Asians than in European-ancestry
populations for some of the index SNPs. Some SNPs were
imputed in the ABCC data set, and thus imputation accuracy
may affect the risk estimate. However, we included in the ana-
lysis only SNPs that were imputed with high quality (RSQ .
0.5, mean RSQ ¼ 0.92). Furthermore, all SNPs were directly
genotyped in the COGS data set, which should facilitate
direct comparison of the results obtained in the Asian and
European-ancestry samples included in the COGS project.
Additional studies, including fine-mapping and functional
characterization of SNPs, are needed to clarify the reasons
for the different associations observed between Asian- and
European-ancestry populations.
In conclusion, our study replicated all five breast cancer
risk variants identified previously in GWASs conducted
in East Asians and found that nearly half of the variants iden-
tified initially in European-ancestry GWASs can be directly
replicated in East Asians. These results show the complexity
of uniformly applying GWAS findings across ancestral
groups. Common genetic variants identified to date explain
14% of familial relative risk (FRR) of breast cancer
in European-ancestry populations (27) but only 10% in
East Asians. The lower estimated FRR in Asian- than in
European-ancestry populations is expected since most
known common genetic variants for breast cancer were
identified in GWASs conducted in European-ancestry popu-
lations, and most of these risk variants show a stronger asso-
ciation with breast cancer risk in European- than in
Asian-ancestry populations. It is possible that other risk var-
iants may exist in some of the loci that could show a stronger
association with breast cancer risk in Asians than the variants
analyzed in this study. It is also possible that multiple
independent risk variants may exist in some of the loci we
evaluated. Fine-mapping of known breast cancer susceptibil-
ity loci may identify breast cancer risk variants more relevant
in Asians than those identified initially in GWASs of
European-ancestry populations, which could improve risk
assessment in Asians.
Table 5. Breast cancer-associated SNPs at 67 susceptibility loci showing a different association by ER status: results from East Asian women
SNP Chr./genea Positionb (bp) Allelesc ER positive ER negative
OR (95% CI)d Pmeta OR (95% CI)
d Pmeta Pheterogeneity
e
rs10941679 5p12/MRPS30 44 742 255 G/A 1.11 (1.06–1.16) 5.44 × 1026 1.01 (0.95–1.07) 0.787 0.009
rs2046210 6q25/ESR1 151 990 059 A/G 1.23 (1.19–1.27) 4.60 × 10232 1.36 (1.31–1.42) 6.04 × 10249 1.10 × 1024
rs1219648 10q26/FGFR2 123 336 180 G/A 1.20 (1.15–1.25) 2.55 × 10217 1.08 (1.02–1.14) 0.0055 0.002
rs204247 6p23/RANBP9 13 830 502 A/G 0.96 (0.92–0.99) 0.021 1.03 (0.98–1.08) 0.235 0.018
rs11199914 10q26/FGFR2 123 083 891 T/C 0.94 (0.89–0.99) 0.011 1.03 (0.96–1.09) 0.399 0.026
rs12422552 12p13/ATF7IP 14 305 198 C/G 1.09 (1.03–1.15) 0.003 0.98 (0.92–1.06) 0.647 0.030
rs527616 18q11/AQP4 22 591 422 G/C 1.06 (1.02–1.10) 0.006 0.97 (0.92–1.02) 0.276 0.010
rs6001930 22q13/MKL1 39 206 180 C/T 1.07 (1.02–1.11) 0.002 0.98 (0.93–1.03) 0.398 0.011
Chr., chromosome; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval.
aThe closest gene.
bLocation based on NCBI Human Genome Build 36.3.
cEffect/reference alleles based on NCBI Human Genome Build 36.3, dbsnp b126 forward strand.
dOdds ratios based on meta-analysis of ABCC and COGS using a fixed-effect model.
eP-value for heterogeneity between ER-positive and -negative cases was calculated using a Cochran’s Q-test.
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MATERIALS AND METHODS
All methodology, results and interpretation in this study were
reported according to the STREGA guidelines (31) and
STROBE statement (32). Approval was granted from the rele-
vant institutional review boards at all study sites, and all
included participants gave informed consent.
Study populations
This study is a collaborative effort between the ABCC and the
international COGS. The ABCC included 19 963 cases and
21 623 controls from 16 studies (Table 1). Detailed descriptions
of these participating studies and demographic characteristics of
study participants have been published previously (9,13,14,18).
The consortium included 25 983 Chinese women, 11 794
Korean women and 3809 Japanese women. Chinese participants
came from nine studies: Shanghai [n ¼ 13 642, the Shanghai
Breast Cancer Study (SBCS) and Shanghai Breast Cancer Sur-
vival Study (SBCSS), Shanghai Endometrial Cancer Study
(SECS, controls only), Shanghai Women’s Health Study
(SWHS)] (9,33,34), Nanjing (n ¼ 3623) (35), Tianjin (n ¼
3147) (36), Taiwan (n ¼ 2131) (37), Guangzhou (n ¼ 2307)
(18,23) and Hong Kong (n ¼ 1133) (38). Korean participants
came from four studies [the Seoul Breast Cancer Study
(SeBCS) (n ¼ 6179) (24), Korea National Cancer Center (n ¼
1009), Korea Genome Epidemiology Study (KoGES; n ¼
3209) (39) and Korean Hereditary Breast Cancer (KOHBRA;
n ¼ 1397) (40)]. Japanese participants came from three
studies conducted in Hawaii and Los Angeles [n ¼ 1719; the
Multiethnic Cohort Study (MEC) (41)], Nagoya (n ¼ 1288)
(42) and Nagano (n ¼ 802) (43) (Table 1). COGS includes
6269 breast cancer patients and 6624 controls of Asian ancestry
who were recruited by nine studies. Approximately 2600 cases
and 2650 controls were included in both the ABCC and COGS.
After excluding overlapping samples, 23 637 cases and 25 580
controls remained for this study.
Genotyping methods
The ABCC consisted of two GWASs, in which 5285 Chinese
women and 4777 Korean women were scanned primarily
using Affymetrix Genome-Wide Human SNP Array 6.0
(Stage 1). Genotyping protocols for Stage I have been described
elsewhere (9,24). In the Chinese GWASs, the initial 300
samples were genotyped using the Affymetrix GeneChip
Mapping 500K Array Set. The remaining 4985 samples were
genotyped using Affymetrix Genome-Wide Human SNP
Array 6.0. We included one negative control and at least three
positive QC samples from the Coriell Cell Repositories (http://
ccr.coriell.org/) in each of the 96-well plates for Affymetrix
SNP Array 6.0 genotyping. A total of 273 positive QC
samples were successfully genotyped, and the average concord-
ance rate was 99.9% with a median value of 100%. The sex of all
study samples was confirmed to be female. Genetically identical
and unexpected duplicate samples were excluded, as were close
relatives with a pair-wise proportion of identify-by-descent
estimate .0.25. All samples with a call rate ,95% were
excluded. SNPs were excluded if: (i) MAF ,1%; (ii) call rate
,95%; or (iii) genotyping concordance rate ,95% in QC
samples. The final data set included 2918 cases and 2324 con-
trols for 690 947 markers. For the Korean GWASs, Affymetrix
Genome-Wide Human SNP Array 6.0 was also used (24). A
total of 30 QC samples were successfully genotyped, and the
concordance rate was 99.8%. The sex of all samples was con-
firmed to be female. SNPs were excluded if: (i) genotype call
rate ,95%; (ii) MAF ,1% in either cases or controls; (iii) evi-
dence for deviation from Hardy–Weinberg equilibrium (HWE)
at P-value , 1026; or (iv) poor cluster plot in either cases or
controls. After these QC exclusions, the final data set included
2246 cases and 2052 controls for 555 525 markers.
Genotyping for Stage 2 in the ABCC was completed pri-
marily using a custom Illumina Infinium BeadChip and the
iPLEX Sequenom MassArray platform. To compare consist-
ency between Stage-1 (Affymetrix) and Stage-2 genotyping,
we included 43 and 45 Stage-1 samples in the assay using
the Illumina BeadChip and Sequenom platforms, respectively,
which yielded concordance rates of 99.9 and 99.5%, respect-
ively, compared with results obtained from the Affymetrix
6.0 genotyping. Additional QC samples were used in the
Sequenom assay, including one negative control (water), two
blinded duplicates and two samples from the HapMap
project in each 96-well plate. The mean concordance rate
was 99.7% for the blind duplicates and 98.9% for HapMap
samples. Some samples were genotyped using TaqMan
assays, for which assay protocols were developed and vali-
dated at the Vanderbilt Molecular Epidemiology Laboratory,
and assay reagents were provided to investigators who per-
formed the assays. For the MEC study, SNP data needed for
the study were extracted from the data generated using Illu-
mina Human 660W.
Genotyping in COGS was conducted using a custom Illumina
Infinium BeadChip, which included 211 155 SNPs, as part of a
large collaboration for replication of promising associations
selected from GWASs of multiple cancers (27). Individuals
were excluded for any of the following reasons: genotypically
not female XX; overall call rate ,95%; low or high heterozy-
gosity (P , 1026); individuals not concordant with previous
genotyping with BCAC; individuals where genotypes for the
duplicate sample appeared to be from a different individual; or
‘cryptic’ duplicates where phenotypic data indicated that the
individuals were different. For known and cryptic duplicates,
the sample with the lower call rate was excluded. We attempted
to identify first-degree relative pairs using identity-by-state esti-
mates based on approximately 37 000 uncorrelated SNPs. For
apparent first-degree relative pairs, we removed the control
from a case–control pair, otherwise we removed the individual
with the lower call rate. Ethnic outliers were identified by multi-
dimensional scaling, combining COGS data with the three
HapMap2 populations, based on a subset of 37 000 uncorrelated
markers which passed QC (including approximately 1000
selected as ancestry informative markers). Individuals with
.15% minority ancestry, based on the first two components,
were excluded. Although the vast majority of study participants
were of East-Asian origin, women from other Asian regions also
were included in studies from Singapore (SGBCC) (92 Indians
and 180 Malays) and Malaysia (MyBrCa) (152 Indians and 166
Malays). Exclusion of these subjects should not change the
results given the small sample size. Therefore, for these
studies, no exclusions for ethnic outliers were made, but
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principal components analysis adequately corrected for infla-
tion. Principal components analyses were carried out based on
a subset of 37 000 uncorrelated SNPs, and two principal compo-
nents were used for the studies in Asian populations. We
excluded SNPs which had a call rate ,95%, deviated from
HWE in controls at P , 1027, or had genotype discrepancies
in .2% of duplicate samples, across all COGS consortia.
Final analyses were based on 199 961 SNPs.
Statistical analyses
PLINK version 1.07 (http://pngu.mgh.harvard.edu/~purcell/p
link/) was used to analyze genome-wide data obtained in
Stage 1 (44). A set of 4305 SNPs with MAF ≥ 35% and a dis-
tance ≥100 kb between two adjacent SNPs were selected to
evaluate the population structure in the Chinese GWASs. In-
flation factor l was estimated to be 1.04. Similar analyses
were performed for the Korean GWASs, which yielded a l
of 1.04 (24). Inflation factor l is ,1.03 in all eight studies
included in COGS. These data suggest that any population
substructure, if present, should not have any appreciable
effect on the results. ORs associated with each SNP and
95% CIs were estimated using logistic regression implemented
in Plink with adjustment for age.
We used the program MACH 1.0 (28) to impute genotypes
for autosomal SNPs which were present in HapMap Phase II
release 22 for samples included in the Chinese and Korean
GWASs. Only SNPs with imputation quality score RSQ .
0.50 were included in analyses. Dosage data for imputed
SNPs for samples in each Stage-1 study were analyzed using
the program mach2dat (28). Associations between genotype
dosage and breast cancer risk were assessed assuming a
log-additive model. ORs associated with each SNP and 95%
confidence intervals (CIs) were estimated using logistic re-
gression adjusted for age.
Individual data were obtained from each study included in
the ABCC and COGS for two separate pooled analyses.
Results from these two pooled analyses were combined in
meta-analyses performed under a fixed-effects model using
the METAL program (45). Data quality for each study was
evaluated by examining genotyping cluster plots and HWE
in controls for all SNPs. SNPs which failed to meet data QC
criteria were excluded from the analysis. Case–control differ-
ences for selected demographic characteristics and major risk
factors were evaluated using t-tests (for continuous variables)
or x2 tests (for categorical variables). Associations between
SNPs and breast cancer risk were assessed using ORs and
95% CIs derived from logistic regression models. ORs were
estimated for the effect allele based on a log-additive model
and adjusted for age and study site, when appropriate. Strati-
fied analyses by ER status were performed.
The fraction of the FRR explained by a single locus, under a
multiplicative model, can be expressed as ln(l)/ln(lo), where
l is the FRR to offspring of an affected individual due to
the locus, and lo is the overall FRR. lo is assumed to be 1.8
for breast cancer (46). Note that if an individual locus fits a
log-additive model, the formula of l for a single locus is:
l = ( pr
2 + q)
( pr + q)2 ,
where p is the frequency of the risk allele, q ¼ 12 p is the fre-
quency of the reference allele and r is the per-allele relative
risk. We assumed that the risks associated with each locus
combine multiplicatively, and the FRRs also multiply, so
that the combined contribution is using formula:
ln (Pili)/ln(lO).
URLS
PLINK version 1.07, http://pngu.mgh.harvard.edu/~purcell/plink/
MACH 1.0, http://www.sph.umich.edu/csg/abecasis/MACH/
mach2dat, http://www.sph.umich.edu/csg/abecasis/MACH/
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